[2]
Tsuneyama K,Baba H,Morimoto Y,Tsunematsu T,Ogawa H, Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms. The journal of medical investigation : JMI. 2017;
[PubMed PMID: 28373632]
[3]
Kowdley KV,Vuppalanchi R,Levy C,Floreani A,Andreone P,LaRusso NF,Shrestha R,Trotter J,Goldberg D,Rushbrook S,Hirschfield GM,Schiano T,Jin Y,Pencek R,MacConell L,Shapiro D,Bowlus CL, A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of hepatology. 2020 Jul;
[PubMed PMID: 32165251]
Level 1 (high-level) evidence
[4]
Younossi ZM,Ratziu V,Loomba R,Rinella M,Anstee QM,Goodman Z,Bedossa P,Geier A,Beckebaum S,Newsome PN,Sheridan D,Sheikh MY,Trotter J,Knapple W,Lawitz E,Abdelmalek MF,Kowdley KV,Montano-Loza AJ,Boursier J,Mathurin P,Bugianesi E,Mazzella G,Olveira A,Cortez-Pinto H,Graupera I,Orr D,Gluud LL,Dufour JF,Shapiro D,Campagna J,Zaru L,MacConell L,Shringarpure R,Harrison S,Sanyal AJ, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2019 Dec 14;
[PubMed PMID: 31813633]
Level 1 (high-level) evidence
[5]
Neuschwander-Tetri BA,Loomba R,Sanyal AJ,Lavine JE,Van Natta ML,Abdelmalek MF,Chalasani N,Dasarathy S,Diehl AM,Hameed B,Kowdley KV,McCullough A,Terrault N,Clark JM,Tonascia J,Brunt EM,Kleiner DE,Doo E, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (London, England). 2015 Mar 14;
[PubMed PMID: 25468160]
Level 1 (high-level) evidence
[6]
Walters JR,Johnston IM,Nolan JD,Vassie C,Pruzanski ME,Shapiro DA, The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Alimentary pharmacology
[PubMed PMID: 25329562]
[7]
Mudaliar S,Henry RR,Sanyal AJ,Morrow L,Marschall HU,Kipnes M,Adorini L,Sciacca CI,Clopton P,Castelloe E,Dillon P,Pruzanski M,Shapiro D, Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013 Sep;
[PubMed PMID: 23727264]
[8]
Mousa HS,Lleo A,Invernizzi P,Bowlus CL,Gershwin ME, Advances in pharmacotherapy for primary biliary cirrhosis. Expert opinion on pharmacotherapy. 2015 Apr;
[PubMed PMID: 25543678]
Level 3 (low-level) evidence
[9]
Mitro N,Godio C,De Fabiani E,Scotti E,Galmozzi A,Gilardi F,Caruso D,Vigil Chacon AB,Crestani M, Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis. Hepatology (Baltimore, Md.). 2007 Sep;
[PubMed PMID: 17654698]
[10]
Lindor KD, Farnesoid X receptor agonists for primary biliary cirrhosis. Current opinion in gastroenterology. 2011 May;
[PubMed PMID: 21297469]
Level 3 (low-level) evidence
[11]
Chapman RW,Lynch KD, Obeticholic acid-a new therapy in PBC and NASH. British medical bulletin. 2020 May 15;
[PubMed PMID: 32282030]
[13]
Hirschfield GM,Mason A,Luketic V,Lindor K,Gordon SC,Mayo M,Kowdley KV,Vincent C,Bodhenheimer HC Jr,Parés A,Trauner M,Marschall HU,Adorini L,Sciacca C,Beecher-Jones T,Castelloe E,Böhm O,Shapiro D, Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015 Apr;
[PubMed PMID: 25500425]
[14]
Kowdley KV,Luketic V,Chapman R,Hirschfield GM,Poupon R,Schramm C,Vincent C,Rust C,Parés A,Mason A,Marschall HU,Shapiro D,Adorini L,Sciacca C,Beecher-Jones T,Böhm O,Pencek R,Jones D, A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.). 2018 May;
[PubMed PMID: 29023915]
Level 1 (high-level) evidence
[15]
Jhaveri MA,Kowdley KV, New developments in the treatment of primary biliary cholangitis - role of obeticholic acid. Therapeutics and clinical risk management. 2017;
[PubMed PMID: 28860789]
[16]
Fiorucci S,Di Giorgio C,Distrutti E, Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Handbook of experimental pharmacology. 2019;
[PubMed PMID: 31201552]
[18]
Trauner M,Nevens F,Shiffman ML,Drenth JPH,Bowlus CL,Vargas V,Andreone P,Hirschfield GM,Pencek R,Malecha ES,MacConell L,Shapiro D, Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The lancet. Gastroenterology
[PubMed PMID: 30922873]
[19]
Gege C,Hambruch E,Hambruch N,Kinzel O,Kremoser C, Nonsteroidal FXR Ligands: Current Status and Clinical Applications. Handbook of experimental pharmacology. 2019;
[PubMed PMID: 31197565]
[20]
Nevens F,Andreone P,Mazzella G,Strasser SI,Bowlus C,Invernizzi P,Drenth JP,Pockros PJ,Regula J,Beuers U,Trauner M,Jones DE,Floreani A,Hohenester S,Luketic V,Shiffman M,van Erpecum KJ,Vargas V,Vincent C,Hirschfield GM,Shah H,Hansen B,Lindor KD,Marschall HU,Kowdley KV,Hooshmand-Rad R,Marmon T,Sheeron S,Pencek R,MacConell L,Pruzanski M,Shapiro D, A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England journal of medicine. 2016 Aug 18;
[PubMed PMID: 27532829]
[21]
Pencek R,Marmon T,Roth JD,Liberman A,Hooshmand-Rad R,Young MA, Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes, obesity
[PubMed PMID: 27109453]
[22]
Pockros PJ,Fuchs M,Freilich B,Schiff E,Kohli A,Lawitz EJ,Hellstern PA,Owens-Grillo J,Van Biene C,Shringarpure R,MacConell L,Shapiro D,Cohen DE, CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver international : official journal of the International Association for the Study of the Liver. 2019 Nov;
[PubMed PMID: 31402538]
Level 1 (high-level) evidence
[23]
Goet JC,Hirschfield GM, Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines. Frontline gastroenterology. 2019 Jul;
[PubMed PMID: 31281627]
[24]
Eaton JE,Vuppalanchi R,Reddy R,Sathapathy S,Ali B,Kamath PS, Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid. Hepatology (Baltimore, Md.). 2020 Apr;
[PubMed PMID: 31680292]
[25]
Zhang Y,Jackson JP,St Claire RL 3rd,Freeman K,Brouwer KR,Edwards JE, Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. Pharmacology research
[PubMed PMID: 28805978]